Zoetis earns license for Cytopoint skin therapyJanuary 4, 2017Veterinary drug maker Zoetis Inc. in December received a U.S. Department of Agriculture license for Cytopoint, which the Parsippany, N.J., company described as the first monoclonal antibody (mAb) therapy approved “to help provide sustained control of the clinical signs associated with atopic dermatitis in dogs.”
SPONSORED CONTENTLet's help them fight the urge to itchHill’s Derm Complete is formulated to help reduce allergic responses, including licking, scratching, headshaking and skin redness + Tell Me More
